Thrombolytic therapy use UFH infusion Greater experience with its use in patients treated with thrombolytic therapy Reversal agent needed VKA, UFH Pregnancy or pregnancy risk LMWH Potential for other agents to cross the placenta Cost, coverage, licensing Varies among regions and with individual circumstances INR International Normalized Ratio; NOAC non-vitamin K oral coagulant. See Table 1 legend for expansion of other abbreviations. 326 Evidence-Based Medicine [ 1 4 9 # 2 C H E S T F E B R U A R Y 2 0 1 6 ] proximal DVT or PE was 50% higher (1.5-fold) than after a rst unprovoked event.57,58 For the decision about whether to stop treatment at 3 months or to treat inde nitely ( extended treatment ), we categorized a patient s risk of bleeding on anticoagulant therapy as low (no bleeding risk factors; 0.8% annualized risk of major bleeding), moderate (one bleeding risk factor; 1.6% annualized risk of major bleeding), or high (two or TABLE 7 ] Summary of Findings: Dabigatran vs VKA for Extended Treatment of VTEa,b,c,d Outcomes No. of Participants (Studies) Quality of the Evidence (GRADE) Relative Effect Anticipated Absolute Effects Risk with VKA Risk Difference with Dabigatran (95% CI) All-cause mortality 2,856 Moderatee,f because of imprecision (from 7 fewer to 9 more) Recurrent VTE 2,856 Moderatee,f,g because of imprecision (from 3 fewer to 20 more) Major bleeding 2,856 Moderatee,f because of imprecision (from 13 fewer to 0 more) The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). REMEDY Secondary Prevention of Venous Thrombo Embolism. 